Thrombosis and systemic lupus erythematosus: The hopkins lupus cohort perspective

Research output: Contribution to journalShort surveypeer-review


Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.

Original languageEnglish (US)
Pages (from-to)191-193
Number of pages3
JournalScandinavian Journal of Rheumatology
Issue number4
StatePublished - 1996


  • Anticardiolipin
  • Antiphospholipid antibodies
  • Lupus anticoagulant
  • Thrombosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology


Dive into the research topics of 'Thrombosis and systemic lupus erythematosus: The hopkins lupus cohort perspective'. Together they form a unique fingerprint.

Cite this